Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Avidity Biosciences, Inc. (RNA) FCF Margin (2019 - 2025)

Avidity Biosciences' FCF Margin history spans 7 years, with the latest figure at 20852.21% for Q4 2025.

  • For Q4 2025, FCF Margin fell 1739980.0% year-over-year to 20852.21%; the TTM value through Dec 2025 reached 3539.11%, down 74665.0%, while the annual FY2025 figure was 3539.11%, 74665.0% down from the prior year.
  • FCF Margin reached 20852.21% in Q4 2025 per RNA's latest filing, down from 1263.07% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 570.5% in Q4 2023 to a low of 20852.21% in Q4 2025.
  • Average FCF Margin over 5 years is 3119.11%, with a median of 1687.56% recorded in 2022.
  • Peak YoY movement for FCF Margin: surged 192293bps in 2023, then plummeted -1739980bps in 2025.
  • A 5-year view of FCF Margin shows it stood at 1610.21% in 2021, then grew by 16bps to 1352.44% in 2022, then skyrocketed by 142bps to 570.5% in 2023, then tumbled by -705bps to 3452.4% in 2024, then plummeted by -504bps to 20852.21% in 2025.
  • Per Business Quant, the three most recent readings for RNA's FCF Margin are 20852.21% (Q4 2025), 1263.07% (Q3 2025), and 5154.17% (Q2 2025).